Wolfgang Oster
Directeur/Membre du Conseil chez IMI Intelligent Medical Implants AG
Profil
Wolfgang Oster is the founder of Oncoceutics, Inc. which was founded in 2009.
He held the title of Chairman & Chief Executive Officer at Oncoceutics, Inc. Dr. Oster's current job(s) include being a Director at IMI Intelligent Medical Implants AG since 2009 and holding the title of Principal at the University of Freiburg.
Dr. Oster's former job(s) include being Vice Chairman at Cappella, Inc. from 2010 to 2011, being a Member-Management Board at AplaGen GmbH, and being a Managing Partner at PolyTechnos Venture-Partners GmbH.
Postes actifs de Wolfgang Oster
| Sociétés | Poste | Début |
|---|---|---|
IMI Intelligent Medical Implants AG
 IMI Intelligent Medical Implants AG Medical DistributorsDistribution Services IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception. The company was founded in 2002 and has 30 employees. The company has a process oriented quality management system in accordance with ISO 13485. | Directeur/Membre du Conseil | 27/04/2010 |
| University of Freiburg | Corporate Officer/Principal | - |
Anciens postes connus de Wolfgang Oster
| Sociétés | Poste | Fin |
|---|---|---|
AplaGen GmbH
 AplaGen GmbH BiotechnologyHealth Technology AplaGen was founded in April 2001 by Prof. Dr. med. Hans-Georg Frank, Prof. Dr. med. Peter Kaufmann and Dr. Franzpeter Bracht. Its basic technologies were a spin-off of the University of Technology Aachen, Germany (RWTH). From this starting point, AplaGen has transformed into a company with broad expertise in peptide design, synthesis and analysis. It has successfully developed own products with independent patent protection for major markets, including the anemia market (EPO-market) and the thrombocytopenia market. The discovery of cytokine-mimetic peptides defines its core expertise. With its proprietary cytokine-mimetic peptide products, AplaGen is approaching large existing biopharmaceutical markets in a 'smart-follower' position, which provides an optimal risk/chance profile. Pharmacokinetic optimization of peptides is based on the approved drug Hydroxyethylstarch (HES) and protected by AplaGen´s IP. As privately held company, AplaGen has closed seed financing in 2001 and a series financing in 2005. AplaGen is dedicated to improvements for patients with dysfunctional bone marrow, especially oncologic patients. Both, erythropoietin and Thrombopoietin mimetic peptides will be developed by AplaGen at least until Phase II. To support this focus on oncologic indications AplaGen is seeking early partners for the erythropoietin mimetic peptide in the indication of renal anemia. | Corporate Officer/Principal | 01/06/2009 |
Oncoceutics, Inc.
 Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Directeur Général | - |
PolyTechnos Venture-Partners GmbH
 PolyTechnos Venture-Partners GmbH Investment ManagersFinance PolyTechnos Venture-Partners II GmbH (PTVP) is an independent partner-owned European private equity firm established in 1998 and based in Munich with a U.S. office in Silicon Valley. Their clients include financial institutions, banks, insurance companies, universities, foundations, corporations and fund-of-funds. They operate in close relationship with U.S. venture capital firms based on the West Coast. PTVP manages and divests a portfolio of private equity participations held through two maturing funds, namely the German fund PolyTechnos Venture Fund II and the UK fund Enabling Technology. PTVP's successor firm PT Capital-Partners GmbH was established in 2008. | Private Equity Investor | - |
Cappella, Inc.
 Cappella, Inc. Pharmaceuticals: MajorHealth Technology Cappella, Inc. operates as a medical device company, which develops novel solutions for the treatment of complex coronary artery disease (CAD) and specifically bifurcation vascular disease. The company was founded by Antonio Columbo and Ascher Shmulewitz in 2004 and is headquartered in Boston, MA. | Président | 05/08/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Cappella, Inc.
Cappella, Inc. Pharmaceuticals: MajorHealth Technology Cappella, Inc. operates as a medical device company, which develops novel solutions for the treatment of complex coronary artery disease (CAD) and specifically bifurcation vascular disease. The company was founded by Antonio Columbo and Ascher Shmulewitz in 2004 and is headquartered in Boston, MA. | Health Technology |
IMI Intelligent Medical Implants AG
IMI Intelligent Medical Implants AG Medical DistributorsDistribution Services IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception. The company was founded in 2002 and has 30 employees. The company has a process oriented quality management system in accordance with ISO 13485. | Distribution Services |
AplaGen GmbH
AplaGen GmbH BiotechnologyHealth Technology AplaGen was founded in April 2001 by Prof. Dr. med. Hans-Georg Frank, Prof. Dr. med. Peter Kaufmann and Dr. Franzpeter Bracht. Its basic technologies were a spin-off of the University of Technology Aachen, Germany (RWTH). From this starting point, AplaGen has transformed into a company with broad expertise in peptide design, synthesis and analysis. It has successfully developed own products with independent patent protection for major markets, including the anemia market (EPO-market) and the thrombocytopenia market. The discovery of cytokine-mimetic peptides defines its core expertise. With its proprietary cytokine-mimetic peptide products, AplaGen is approaching large existing biopharmaceutical markets in a 'smart-follower' position, which provides an optimal risk/chance profile. Pharmacokinetic optimization of peptides is based on the approved drug Hydroxyethylstarch (HES) and protected by AplaGen´s IP. As privately held company, AplaGen has closed seed financing in 2001 and a series financing in 2005. AplaGen is dedicated to improvements for patients with dysfunctional bone marrow, especially oncologic patients. Both, erythropoietin and Thrombopoietin mimetic peptides will be developed by AplaGen at least until Phase II. To support this focus on oncologic indications AplaGen is seeking early partners for the erythropoietin mimetic peptide in the indication of renal anemia. | Health Technology |
PolyTechnos Venture-Partners GmbH
PolyTechnos Venture-Partners GmbH Investment ManagersFinance PolyTechnos Venture-Partners II GmbH (PTVP) is an independent partner-owned European private equity firm established in 1998 and based in Munich with a U.S. office in Silicon Valley. Their clients include financial institutions, banks, insurance companies, universities, foundations, corporations and fund-of-funds. They operate in close relationship with U.S. venture capital firms based on the West Coast. PTVP manages and divests a portfolio of private equity participations held through two maturing funds, namely the German fund PolyTechnos Venture Fund II and the UK fund Enabling Technology. PTVP's successor firm PT Capital-Partners GmbH was established in 2008. | Finance |
Oncoceutics, Inc.
Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Health Technology |